News

Nutrition 21 has posted a net loss of $3.66m for the full year ended 30 June 2010, or $0.04 loss per diluted share, compared to a net loss

The FDA also granted priority review status for the new drug application and set a Prescription Drug User Fee Act (PDUFA) action date of 7 January 2011. The

The study is expected to recruit a total of 80 patients at investigative sites in Italy, Switzerland and South Africa. CYT107 Phase II study is designed to evaluate

The collaboration is aimed at O-GIcNAcase, a target for Alzheimer’s, that modulates the solubility of the protein in these aggregates but that has been difficult to target with

In conjunction with the sublicensing agreement, Topica Pharmaceuticals will now focus on developing Luliconazole exclusively for the treatment of onychomycosis. Reportedly, in February of 2010 the company’s IND

The combined entity, called Valeant Pharmaceuticals International, will have a significantly expanded presence in North America and operations across eight other countries. The deal is expected to take

The decision comes a year after Marubeni transferred sales and marketing of F310 Polyvinylidene Chloride (PVDC) product to Viachem from Univar’s ChemPoint business unit. Marubeni claimed that its

The new oxymorphone formulation is a semi-synthetic opioid analgesic intended for the treatment of moderate to severe chronic pain in patients requiring continuous, around-the-clock opioid treatment for an

Tamaris is a randomised, double blind, placebo controlled study designed to evaluate the safety and efficacy of NV1FGF in patients with critical limb ischemia and skin lesions who